Sanofi Offers to Acquire Kiadis
On 2 November 2020, Kiadis and Sanofi announced that they reached agreement on a recommended public offer by Sanofi for the entire issued and outstanding share capital of Kiadis, for an offer price of EUR 5.45 (cum dividend) per Kiadis share.
With the publication of the Offer Memorandum on 12 February 2021, the offer was launched and, as of 15 February 2021, shareholders can accept the offer by tendering their Kiadis shares. Shareholders can tender their shares until 12 April 2021, 17:40 hours CET, unless the acceptance period is extended in accordance with Section 5.10. of the Offer Memorandum. Shareholders are advised to contact their financial intermediary, who may set an earlier deadline than 12 April 2021, in order to communicate the acceptances to the Settlement Agent in a timely manner.
On 12 February 2021, the management board and supervisory board of Kiadis also published their Position Statement regarding the offer. In this document they explain why they support the offer and recommend to shareholders to accept it.
On this page you will find all information and documents related to the offer. The Offer Memorandum and the Position Statement contain important information that should be carefully read before a decision is made to tender Kiadis shares under the offer.
If there are any questions, please contact Investor Relations by email at info@kiadis.com. Retail investors can also contact SanofiofferforKiadis@georgeson.com or phone to + 31 10 313 8909.